接受后Tenon囊下曲安奈德深部注射的多发性硬化症患者葡萄膜炎黄斑水肿的定量分析

Quantitative Analysis of Uveitis Macular Edema in Multiple Sclerosis Patients Receiving Deep Posterior Sub-Tenon Triamcinolone Acetonide Injection.

作者信息

Jovanović Svetlana, Šarenac Vulović Tatjana, Radotić Filip, Tončić Zorica, Živković Maja, Petrović Nenad

机构信息

Department of Ophthalmology, Clinical Center Kragujevac, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.

出版信息

Ophthalmic Res. 2017;58(1):1-7. doi: 10.1159/000458157. Epub 2017 Mar 22.

DOI:10.1159/000458157

PMID:28324879

Abstract

AIM

We aimed to analyze the effects of adjunctive posterior sub-Tenon capsule triamcinolone acetonide injection in the treatment of intermediate uveitis macular edema in multiple sclerosis patients that could not be controlled by systemic corticosteroid medications and immunomodulators.

METHODS

The study included 30 eyes of 25 patients with multiple sclerosis who received a posterior sub-Tenon injection of 40 mg/mL triamcinolone acetonide. Parameters monitored for therapy efficiency were best-corrected visual acuity, intraocular pressure, central foveal thickness (CFT), and fluorescein angiography (FA) scores.

RESULTS

Mean best-corrected visual acuity was significantly improved at the control visit 0.15 ± 0.10 versus baseline 0.40 ± 0.20 logMAR (p < 0.05). Six eyes showed intraocular pressure spikes requiring topical antiglaucomatous treatment. Mean CFT and FA scores were significantly decreased versus baseline (CFT: 345 ± 50 μm; FA score: 3.4 ± 1.0) compared with the 12-week control visit (CFT: 219 ± 35 μm; FA score: 1.6 ± 1.1; p < 0.001).

CONCLUSION

Posterior sub-Tenon injection of triamcinolone acetonide significantly improved visual acuity and decrease macular edema in patients with intermediate uveitis associated with multiple sclerosis.

摘要

目的

我们旨在分析辅助性后Tenon囊下注射曲安奈德对无法通过全身皮质类固醇药物和免疫调节剂控制的多发性硬化症患者中间葡萄膜炎黄斑水肿的治疗效果。

方法

该研究纳入了25例接受40mg/mL曲安奈德后Tenon囊下注射的多发性硬化症患者的30只眼。监测治疗效果的参数包括最佳矫正视力、眼压、中心凹厚度（CFT）和荧光素血管造影（FA）评分。

结果

在对照访视时，平均最佳矫正视力显著提高，0.15±0.10（logMAR），而基线时为0.40±0.20（logMAR）（p<0.05）。6只眼出现眼压峰值，需要局部抗青光眼治疗。与基线相比，平均CFT和FA评分显著降低（CFT：345±50μm；FA评分：3.4±1.0），而12周对照访视时为（CFT：219±35μm；FA评分：1.6±1.1；p<0.001）。